ORION CLASS B overview

ORION CORPORATION PRESS RELEASE 15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 Orion will publish Interim Report for January–September 2024 on Tuesday, 29 October 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts,...

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic...

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion’s near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated our near-term science-based targets. This means that our greenhouse gas (GHG) emissions reduction targets align with the latest climate science to limit global warming to 1.5°C above pre-industrial levels. Orion Corporation commits to reduce...

ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster Orion’s collaboration partner Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of...

ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today that the companies have entered into agreement to create new Gemini Digital Twins to help in the fight against cancer. Cancer is a critical...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 SEPTEMBER 2024 at 9.30 EEST 213,285 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 213,285 A shares have been converted into 213,285 B shares. The conversion has been entered into the Trade Register on 20 September 2024. The total number of shares in Orion Corporation is 141,134,278 which, after...

ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year. Due to these...